Sign In
Buy DGX
$235.84
+2.12 (+0.91%)
At Close: Aug 05, 2026
Quest Diagnostics Beats Q2 Earnings & Revenue Estimates, Stock Rises
09:40am, Tuesday, 22'nd Jul 2025
DGX tops Q2 estimates with 15.2% revenue growth and a strong EPS beat, lifting the stock 3.2% in pre-market trading.
Quest Diagnostics (DGX) Beats Q2 Earnings and Revenue Estimates
08:56am, Tuesday, 22'nd Jul 2025
Quest Diagnostics (DGX) came out with quarterly earnings of $2.62 per share, beating the Zacks Consensus Estimate of $2.57 per share. This compares to earnings of $2.35 per share a year ago.
Quest Diagnostics raises annual forecasts on strong diagnostic testing demand
07:17am, Tuesday, 22'nd Jul 2025
Laboratory operator Quest Diagnostics raised its 2025 profit and revenue forecasts on Tuesday, banking on robust demand for its diagnostic tests, sending the company's shares up over 3% in premarket t
Quest Diagnostics Reports Second Quarter 2025 Financial Results; Raises Guidance for Full Year 2025
06:47am, Tuesday, 22'nd Jul 2025
Second quarter revenues of $2.76 billion, up 15.2% from 2024 Second quarter reported diluted earnings per share ("EPS") of $2.47, up 21.7% from 2024; and adjusted diluted EPS of $2.62, up 11.5% from 2
Should You Buy Quest Diagnostics Ahead of Earnings?
09:41am, Monday, 21'st Jul 2025
DGX is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
DGX Q2 Earnings Preview: Will Advanced Diagnostics Lead Performance?
09:05am, Monday, 21'st Jul 2025
Quest Diagnostics' Q2 results may get a lift from Advanced Diagnostics, new health plan deals and recent acquisitions.
Will Quest Diagnostics (DGX) Beat Estimates Again in Its Next Earnings Report?
01:11pm, Thursday, 17'th Jul 2025
Quest Diagnostics (DGX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Quest Diagnostics (DGX) is a Top-Ranked Value Stock: Should You Buy?
10:41am, Tuesday, 15'th Jul 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Quest Diagnostics Introduces Testing for Oropouche Virus
07:57am, Tuesday, 15'th Jul 2025
Diagnostic testing for emerging infectious disease associated with severe neurological affects SECAUCUS, N.J. , July 15, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic inf
Quest Diagnostics: Buy Into Future Patient Demand, At An Undervalued Price Today
07:36am, Tuesday, 15'th Jul 2025
For my initial rating of Quest Diagnostics (DGX), I'm calling it a buy. Forecasts point to continuing demand for diagnostic testing, while the company also grew its business via acquisitions and new s
Quest Diagnostics to Offer FDA-Cleared Fujirebio Blood Test for Alzheimer's Disease
08:24am, Wednesday, 09'th Jul 2025
Test to be available for clinical and research use as soon as this summer, building on Quest's pioneering blood-based AD-Detect™ product line for assessing symptomatic patients SECAUCUS, N.J. , July
Quest Diagnostics Stock Climbs 27.3% in a Year: What's Fueling It?
09:01am, Monday, 07'th Jul 2025
DGX stock surges 27.3% in a year, fueled by Advanced Diagnostics, key acquisitions and expanding health plan ties.
4 Stocks to Watch in a Rapidly Shifting Outpatient Home Health Space
11:10am, Wednesday, 02'nd Jul 2025
An aging global population and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry despite the macroeconomic challenges. DGX, EHC, DVA and PNTG are well-poised
Is Quest Diagnostics Stock a Smart Pick for Your Portfolio Now?
09:51am, Wednesday, 02'nd Jul 2025
DGX rides on double-digit diagnostics growth and a wave of strategic acquisitions despite rising debt and policy headwinds.
Quest Diagnostics (DGX) Upgraded to Buy: Here's What You Should Know
01:01pm, Friday, 27'th Jun 2025
Quest Diagnostics (DGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
